BetterLife Pharma (BETRF) Profit After Tax (2010 - 2026)
BetterLife Pharma (BETRF) posted quarterly Profit After Tax of -$426847.8 for Q2 2026, down 95.51% year-over-year from -$9.5 million in Q2 2025, and down 12.4% quarter-over-quarter from -$379762.0 in Q3 2025.
BetterLife Pharma (BETRF) Profit After Tax (2010 - 2026) Analysis & Trends
BetterLife Pharma's Profit After Tax history runs 17 years deep, the most recent figure standing at -$426847.8 for Q2 2026.
- In Q2 2026, Profit After Tax fell 95.51% year-over-year to -$426847.8; the TTM figure through Apr 2026 stood at -$589485.1 (up 50.24% YoY), while the FY2026 annual figure was -$1.1 million, up 57.27% from the prior year.
- Profit After Tax for Q2 2026 stood at -$426847.8, down from -$379762.0 in the prior quarter.
- The five-year high for Profit After Tax was $435450.6 in Q1 2025, with the low at -$3.5 million in Q4 2022.
- The 5-year median for Profit After Tax is -$671923.4 (2023), against an average of -$1.0 million.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax plunged 140.52% in 2024, then surged 311.64% in 2025.
- BetterLife Pharma's Profit After Tax stood at -$3.5 million in 2022, then surged by 82.07% to -$631648.0 in 2023, then increased by 13.21% to -$548219.9 in 2024, then surged by 30.73% to -$379762.0 in 2025, then declined by 12.4% to -$426847.8 in 2026.
- Business Quant data shows BETRF's Profit After Tax at -$426847.8 in Q2 2026, -$379762.0 in Q3 2025, and -$218325.9 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | BetterLife Pharma | 36.45 Mn | 36.42 Mn | - | -446,911.44 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -426,847.83 |
| Jul 31, 2025 | -379,762.02 |
| Apr 30, 2025 | -218,325.86 |
| Jan 31, 2025 | 435,450.62 |
| Oct 31, 2024 | -548,219.88 |
| Jul 31, 2024 | -853,557.23 |
| Apr 30, 2024 | -1.71 Mn |
| Jan 31, 2024 | -205,750.57 |
| Oct 31, 2023 | -631,648.03 |
| Jul 31, 2023 | -769,896.81 |
| Apr 30, 2023 | -712,198.78 |
| Jan 31, 2023 | -429,833.05 |
| Oct 31, 2022 | -3.52 Mn |
| Jul 31, 2022 | -874,795.77 |
| Apr 30, 2022 | -2.36 Mn |
| Jan 31, 2022 | -3.11 Mn |
| Oct 31, 2021 | -1.76 Mn |
| Jul 31, 2021 | -2.91 Mn |
| Apr 30, 2021 | -1.95 Mn |
| Jan 31, 2021 | -23.83 Mn |